Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023890 (
cirrhosis
)
42,195
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Branched-chain alpha-keto acid dehydrogenase
(
BCKDH
) complex catalyzes the committed step of the catabolism of branched-chain amino acids (BCAA). The
liver cirrhosis
chemically induced in rats raised the activity of hepatic
BCKDH
complex and decreased plasma BCAA and branched-chain alpha-keto acid concentrations, suggesting that the BCAA requirement is increased in
liver cirrhosis
. Since the effects of
liver cirrhosis
on the
BCKDH
complex in human liver are different from those in rat liver, further studies are needed to clarify the differences between rats and humans. In the valine catabolic pathway, crotonase and beta-hydroxyisobutyryl-CoA hydrolase are very important to regulate the toxic concentration of mitochondrial methacrylyl-CoA, which occurs in the middle part of valine pathway and highly reacts with free thiol compounds. Both enzyme activities in human and rat livers are very high compared to that of
BCKDH
complex. It has been found that both enzyme activities in human livers were significantly reduced by
liver cirrhosis
and hepatocellular carcinoma, suggesting a decrease in the capability to dispose methacrylyl-CoA. The findings described here suggest that alterations in hepatic enzyme activities in the BCAA catabolism are associated with liver failure.
...
PMID:Effects of liver failure on the enzymes in the branched-chain amino acid catabolic pathway. 1468 72
Branched-chain alpha-keto acid dehydrogenase
(
BCKDH
) complex, the enzyme catalyst for the second step of the BCAA catabolic pathway, plays a central role in the regulation of BCAA catabolism. The activity of the complex is regulated by a covalent modification cycle in which phosphorylation by
BCKDH
kinase inactivates and dephosphorylation by BCKDH phosphatase activates the complex. Many studies suggest that control of the activity of the kinase is a primary determinant of the activity of the complex. The kinase exists at all times in the mitochondrial matrix space in two forms, with a large amount being free and a smaller amount bound rather tightly to the
BCKDH
complex. Only the bound form of the kinase appears to be catalytically active and, therefore, responsible for phosphorylation and inactivation of the complex. alpha-Ketoisocaproate, the transamination product of leucine and the most important known physiological inhibitor of
BCKDH
kinase, promotes release of the kinase from the complex. alpha-Chloroisocaproate, the analogue of leucine and the most potent known inhibitor of the kinase, is more effective than alpha-ketoisocaproate in promoting release of
BCKDH
kinase from the complex. Exercise and chronic liver disease (
liver cirrhosis
) likewise decrease the amount of the kinase bound to the complex in rat liver. The resulting activation of the
BCKDH
complex appears responsible for the increase in BCAA catabolism caused by exercise and
liver cirrhosis
. Our findings support the use of BCAA supplements for patients with
liver cirrhosis
.
...
PMID:Branched-chain amino acid catabolism in exercise and liver disease. 1636 92